Suppr超能文献

肉毒杆菌毒素:最新进展。

Botulinum toxin: State of the art.

作者信息

Jankovic Joseph

机构信息

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

出版信息

Mov Disord. 2017 Aug;32(8):1131-1138. doi: 10.1002/mds.27072. Epub 2017 Jun 22.

Abstract

Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. © 2017 International Parkinson and Movement Disorder Society.

摘要

肉毒杆菌神经毒素(BoNT)已成为现代医学中用途最广泛的治疗药物之一,其临床应用比目前市场上的任何其他药物都要多。肉毒杆菌神经毒素最初用于治疗斜视和神经运动障碍,在过去30年中,其应用范围不断扩大,包括治疗各种眼科、胃肠道、泌尿科、骨科、皮肤科、牙科、分泌性、疼痛性、美容性及其他病症。除了A型肉毒毒素(保妥适)、A型肉毒毒素(得保松)、A型肉毒毒素(泽明)和B型肉毒毒素(迈保生或纽保生)外,目前还有其他新型肉毒杆菌神经毒素产品正在研发中。随着对肉毒杆菌神经毒素细胞机制的深入了解以及生物技术的进步,未来的肉毒杆菌神经毒素产品可能会更加有效,并针对特定适应症进行定制,以满足患者的需求。© 2017国际帕金森病和运动障碍协会。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验